A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Part of paid clinical trials in Fresno, California.

Sponsor
Novo Nordisk A/S
Study ID
NCT01952145
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • insulin degludec/liraglutide — DRUG
    Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
  • insulin glargine — DRUG
    Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.

Study Details

This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.

Key Dates

Start date
Sep 20, 2013
Status verified
Dec 2018
Primary completion
Nov 4, 2014
Completion
Nov 4, 2014

Study Design

Enrollment
557 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Insulin degludec/liraglutide OD plus metformin
  • Active Comparator: Insulin glargine OD plus metformin

Primary Outcome Measure

Change From Baseline in HbA1c (Glycosylated Haemoglobin) [ Time Frame: Week 0, week 26 ]

Locations (31)

FacilityCityStateZIPSite coordinators
Novo Nordisk Investigational SiteFresnoCalifornia93720-
Novo Nordisk Investigational SiteLos AlamitosCalifornia90720-
Novo Nordisk Investigational SitePalm SpringsCalifornia92262-
Novo Nordisk Investigational SiteSan DiegoCalifornia92111-
Novo Nordisk Investigational SiteColorado SpringsColorado80906-
Novo Nordisk Investigational SiteColorado SpringsColorado80909-
Novo Nordisk Investigational SiteBradentonFlorida34201-
Novo Nordisk Investigational SiteFort LauderdaleFlorida33316-
Novo Nordisk Investigational SiteMiamiFlorida33165-
Novo Nordisk Investigational SitePembroke PinesFlorida33027-
Novo Nordisk Investigational SiteTampaFlorida33603-
Novo Nordisk Investigational SiteGurneeIllinois60031-
Novo Nordisk Investigational SiteEvansvilleIndiana47725-
Novo Nordisk Investigational SiteMichigan CityIndiana46360-
Novo Nordisk Investigational SiteLexingtonKentucky40503-
Novo Nordisk Investigational SiteLouisvilleKentucky40213-
Novo Nordisk Investigational SiteSlidellLouisiana70461-4231-
Novo Nordisk Investigational SiteSaint CharlesMissouri63303-
Novo Nordisk Investigational SiteWilmingtonNorth Carolina28401-
Novo Nordisk Investigational SiteFranklinOhio45005-
Novo Nordisk Investigational SiteOklahoma CityOklahoma73103-
Novo Nordisk Investigational SiteOklahoma CityOklahoma73104-
Novo Nordisk Investigational SiteAltoonaPennsylvania16602-
Novo Nordisk Investigational SitePhiladelphiaPennsylvania19140-
Novo Nordisk Investigational SiteColliervilleTennessee38017-
Novo Nordisk Investigational SiteKingsportTennessee37660-
Novo Nordisk Investigational SiteDallasTexas75390-9302-
Novo Nordisk Investigational SiteSan AntonioTexas78224-
Novo Nordisk Investigational SiteWest JordanUtah84088-8871-
Novo Nordisk Investigational SiteRentonWashington98057-
Novo Nordisk Investigational SiteSpokaneWashington99218-

Find similar trials in Fresno, CA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Novo Nordisk Investigational Site· Fresno, CANovo Nordisk Investigational Site· Los Alamitos, CANovo Nordisk Investigational Site· Palm Springs, CANovo Nordisk Investigational Site· San Diego, CANovo Nordisk Investigational Site· Colorado Springs, CONovo Nordisk Investigational Site· Bradenton, FL

Related Studies